MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said on Tuesday it has agreed to buy GlaxoSmithKline's opiates business in Australia.
The business includes two manufacturing sites in Tasmania and Victoria, and consists of poppy-derived opiate raw materials mainly used to make analgesics for pain treatment.
Financial details of the deal were not disclosed.
"The acquisition is a part of our strategy towards building our portfolio of opiates and accessing strong capabilities in this segment," Iftach Seri, executive vice president of the active pharmaceuticals ingredients business at Sun Pharma, said in a statement.
(Reporting by Zeba Siddiqui in Mumbai; Editing by Sunil Nair)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app